XBI vs. LABU
XBI (SPDR S&P Biotech ETF) and LABU (Direxion Daily S&P Biotech Bull 3x Shares) are both exchange-traded funds - XBI is a Health & Biotech Equities fund tracking the S&P Biotechnology Select Industry Index, while LABU is a Leveraged Equities fund tracking the S&P Biotechnology Select Industry Index (300%). Both are passively managed. Over the past 10 years, XBI returned 11.06%/yr vs -7.38%/yr for LABU. With a 1.00 correlation, they move nearly in lockstep. XBI charges 0.35%/yr vs 1.12%/yr for LABU.
Performance
XBI vs. LABU - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, XBI achieves a 19.74% return, which is significantly lower than LABU's 44.31% return. Over the past 10 years, XBI has outperformed LABU with an annualized return of 11.06%, while LABU has yielded a comparatively lower -7.38% annualized return.
XBI
- 1D
- 3.75%
- 1M
- 10.89%
- YTD
- 19.74%
- 6M
- 15.96%
- 1Y
- 77.88%
- 3Y*
- 19.92%
- 5Y*
- 1.79%
- 10Y*
- 11.06%
LABU
- 1D
- 11.19%
- 1M
- 31.29%
- YTD
- 44.31%
- 6M
- 30.68%
- 1Y
- 313.64%
- 3Y*
- 22.45%
- 5Y*
- -30.40%
- 10Y*
- -7.38%
XBI vs. LABU - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
XBI SPDR S&P Biotech ETF | 19.74% | 35.89% | 1.01% | 7.60% | -25.87% | -20.45% | 48.33% | 32.56% | -15.28% | 43.77% |
LABU Direxion Daily S&P Biotech Bull 3x Shares | 44.31% | 79.17% | -26.02% | -13.41% | -80.36% | -64.15% | 74.66% | 75.50% | -57.61% | 149.12% |
Correlation
The correlation between XBI and LABU is 1.00 - these two move nearly in lockstep. At this level, holding both provides almost no diversification benefit. If you already own one, adding the other does little to reduce portfolio risk.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 1.00 |
Correlation (3Y) Calculated over the trailing 3-year period | 1.00 |
Correlation (5Y) Calculated over the trailing 5-year period | 1.00 |
Correlation (10Y) Calculated over the trailing 10-year period | 1.00 |
Correlation (All Time) Calculated using the full available price history since May 28, 2015 | 1.00 |
The correlation between XBI and LABU has been stable across timeframes, ranging from 1.00 to 1.00 - a consistent structural relationship.
XBI vs. LABU - Sectors Allocation Comparison
Sectors
XBI
LABU
Healthcare
Financial Services
Basic Materials
Communication Services
-
-
Consumer Cyclical
-
-
Consumer Defensive
-
-
Energy
-
-
Industrials
-
-
Real Estate
-
-
Technology
-
-
Utilities
-
-
Healthcare
XBI
LABU
Financial Services
XBI
LABU
Basic Materials
XBI
LABU
Communication Services
XBI
-
LABU
-
Consumer Cyclical
XBI
-
LABU
-
Consumer Defensive
XBI
-
LABU
-
Energy
XBI
-
LABU
-
Industrials
XBI
-
LABU
-
Real Estate
XBI
-
LABU
-
Technology
XBI
-
LABU
-
Utilities
XBI
-
LABU
-
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
XBI vs. LABU — Risk / Return Rank
XBI
LABU
XBI vs. LABU - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for SPDR S&P Biotech ETF (XBI) and Direxion Daily S&P Biotech Bull 3x Shares (LABU). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| XBI | LABU | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.05 | ||
| Sortino ratioReturn per unit of downside risk | +0.22 | ||
| Omega ratioGain probability vs. loss probability | 1.46 | 1.43 | +0.03 |
| Calmar ratioReturn relative to maximum drawdown | 8.05 | 10.29 | -2.24 |
| Martin ratioReturn relative to average drawdown | 23.79 | 28.91 | -5.12 |
Loading charts...
Drawdowns
XBI vs. LABU - Drawdown Comparison
The maximum XBI drawdown since its inception was -63.89%, smaller than the maximum LABU drawdown of -99.18%. Use the drawdown chart below to compare losses from any high point for XBI and LABU.
Loading charts...
Drawdown Indicators
| XBI | LABU | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -63.89% | -99.18% | +35.29% |
Max Drawdown (1Y)Largest decline over 1 year | -9.72% | -30.70% | +20.98% |
Max Drawdown (3Y)Largest decline over 3 years | -32.99% | -78.30% | +45.31% |
Max Drawdown (5Y)Largest decline over 5 years | -54.71% | -97.59% | +42.88% |
Max Drawdown (10Y)Largest decline over 10 years | -63.89% | -98.96% | +35.07% |
Current DrawdownCurrent decline from peak | -15.61% | -94.92% | +79.31% |
Average DrawdownAverage peak-to-trough decline | -20.93% | -81.71% | +60.78% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 3.28% | 10.91% | -7.63% |
Volatility
XBI vs. LABU - Volatility Comparison
The current volatility for SPDR S&P Biotech ETF (XBI) is 9.97%, while Direxion Daily S&P Biotech Bull 3x Shares (LABU) has a volatility of 29.77%. This indicates that XBI experiences smaller price fluctuations and is considered to be less risky than LABU based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| XBI | LABU | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 9.97% | 29.77% | -19.80% |
Volatility (6M)Calculated over the trailing 6-month period | 21.32% | 63.11% | -41.79% |
Volatility (1Y)Calculated over the trailing 1-year period | 26.52% | 78.92% | -52.40% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 32.30% | 95.94% | -63.64% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 32.04% | 95.55% | -63.51% |
XBI vs. LABU - Expense Ratio Comparison
XBI has a 0.35% expense ratio, which is lower than LABU's 1.12% expense ratio.
Dividends
XBI vs. LABU - Dividend Comparison
XBI's dividend yield for the trailing twelve months is around 0.40%, less than LABU's 0.54% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
LABU Direxion Daily S&P Biotech Bull 3x Shares | 0.54% | 0.84% | 0.35% | 0.35% | 0.00% | 0.00% | 0.00% | 0.28% | 0.64% | 0.17% | 0.00% | 0.00% |
XBI SPDR S&P Biotech ETF | 0.40% | 0.37% | 0.15% | 0.02% | 0.00% | 0.04% | 0.20% | 0.00% | 0.28% | 0.24% | 0.26% | 0.61% |
Frequently Asked Questions
With a correlation of 1.00, XBI and LABU move almost identically. Holding both adds very little diversification - you're essentially doubling your position in the same market segment. Choosing one is usually more capital-efficient.
LABU has higher volatility (29.77%) compared to XBI (9.97%). In terms of maximum drawdown, XBI dropped -63.89% vs LABU's -99.18%.
On 10-year performance, XBI leads with 11.06% vs -7.38% for LABU. On fees, XBI is cheaper at 0.35% per year. On volatility, XBI has been the lower-risk option at 9.97%. The better choice depends on whether you care most about return, fees, risk, or income.
Over the 10-year period, XBI has performed better with a 11.06% return vs -7.38%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.
XBI is cheaper with a 0.35% expense ratio, compared with 1.12% for LABU.
LABU has the higher dividend yield at 0.54%, compared with 0.40% for XBI.
XBI is categorized as Health & Biotech Equities, while LABU is Leveraged Equities. XBI tracks S&P Biotechnology Select Industry Index, while LABU tracks S&P Biotechnology Select Industry Index (300%). They also come from different issuers: State Street and Direxion. Their fees differ too: 0.35% for XBI and 1.12% for LABU.
LABU currently has the higher Sharpe Ratio (4.01 vs 2.96), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for XBI and LABU
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer